Lupus News

Among fully vaccinated individuals with rheumatic diseases, breakthrough COVID-19 infections occurred most commonly in patients treated with B cell depleting agents or mycophenolate, according to data presented at ACR Convergence 2021.

Patients with lupus nephritis who receive voclosporin demonstrated “meaningful reductions” in proteinuria with no change in mean estimated glomerular filtration rate at 30 months, according to data presented at ACR Convergence 2021.

The use of vitamin D3 or omega-3 fatty acid supplements over a 5-year period may reduce the incidence of autoimmune disease in older adults by 25% to 30%, according to data presented at ACR Convergence 2021.

Heart rate monitoring may be a crucial means of detecting rhythm abnormalities in the fetuses of pregnant individuals who are positive for anti-Ro/SSA antibodies, according to data presented at ACR Convergence 2021.

Black children with lupus are significantly more likely than white children to have an adverse renal outcome at any hospital encounter, despite an overall decrease in said outcomes since 2006, according to data presented at ACR Convergence 2021.

Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter here.

Race and residence are both independently associated with lupus nephritis mortality, with Black patients and those living in large central metropolitan areas demonstrating the highest rates, according to data presented at ACR Convergence 2021.

Although recent clinical data continue to expand possible treatment options for lupus nephritis, whether belimumab or voclosporin should be the first-line therapy remained hotly contested during the ACR’s annual Great Debate.

One-third of patients with systemic lupus erythematosus demonstrate low response to the COVID-19 vaccine, a “blunted effect” linked to use of any immunosuppressive agent except antimalarials, according to a presenter at ACR Convergence 2021.

The FDA has approved a supplemental new drug application for ANI Pharmaceutical’s Cortrophin Gel to treat rheumatoid arthritis, multiple sclerosis and certain other autoimmune diseases, according to a company press release.